{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:25:33Z","timestamp":1772112333677,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.brachy.2025.10.008","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:21:58Z","timestamp":1764850918000},"page":"300-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["National patterns of brachytherapy boost use for intermediate- and high-risk prostate cancer: Bridging the gap between evidence and practice"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7308-1919","authenticated-orcid":false,"given":"Alicia C.","family":"Smart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-3233","authenticated-orcid":false,"given":"Yetkin","family":"Tuac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grgur","family":"Miri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Orio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-5107","authenticated-orcid":false,"given":"Martin T.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-0951","authenticated-orcid":false,"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2025.10.008_bib0001","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0002","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.008_bib0003","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.008_bib0004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ctrv.2018.10.004","article-title":"Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials","volume":"70","author":"Kee","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.brachy.2025.10.008_bib0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.brachy.2025.10.008_bib0006","series-title":"Edn. presented at the EAU Annual Congress Madrid 2025","year":"2025"},{"key":"10.1016\/j.brachy.2025.10.008_bib0007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0008","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2023.08.046","article-title":"Trimodality therapy with Iodine-125 brachytherapy, external beam radiation therapy, and short- or long-term androgen deprivation therapy for high-risk localized prostate cancer: results of a multicenter, randomized phase 3 trial (TRIP\/TRIGU0907)","volume":"118","author":"Yorozu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7_suppl","key":"10.1016\/j.brachy.2025.10.008_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/jco.2015.33.7_suppl.3","article-title":"ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.008_bib0011","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A randomized trial comparing quality of life after low-dose rate or high-dose rate prostate brachytherapy boost with pelvic external beam radiation therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.008_bib0013","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0014","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2023.11.018","article-title":"A systematic review of the efficacy and toxicity of brachytherapy boost combined with external beam radiotherapy for nonmetastatic prostate cancer","volume":"7","author":"Slevin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0016","article-title":"Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: insights for Stereotactic Body radiotherapy (SBRT) and brachytherapy modalities","volume":"45","author":"Gomez-Iturriaga","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0017","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2021.07.004","article-title":"PSA: declining utilization of prostate brachytherapy","volume":"21","author":"Andring","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.008_bib0018","first-page":"19","article-title":"Real-world utilisation of brachytherapy boost and patient-reported functional outcomes in men who had external beam radiation therapy for prostate cancer in Australia","volume":"37","author":"Ong","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0019","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13014-023-02375-5","article-title":"Use of focal radiotherapy boost for prostate cancer: radiation oncologists\u2019 perspectives and perceived barriers to implementation","volume":"18","author":"Zhong","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2025.10.008_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2021.09.003","article-title":"Increasing global access to brachytherapy: the ABS 300 in 10 initiative and ongoing international efforts","volume":"21","author":"Petereit","year":"2022","journal-title":"Brachytherapy"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:41:10Z","timestamp":1772109670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125003514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1538472125003514"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.10.008","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National patterns of brachytherapy boost use for intermediate- and high-risk prostate cancer: Bridging the gap between evidence and practice","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}